Cefizox (ceftizoxime): Uses, Dosage & Side Effects

What it's for (Indications)

Ceftizoxime is a third-generation cephalosporin antibiotic indicated for the treatment of a wide range of serious bacterial infections caused by susceptible microorganisms.
Its broad spectrum of activity covers various Gram-positive and Gram-negative bacteria.
Specific approved indications include, but are not limited to: lower respiratory tract infections (such as pneumonia and bronchitis) caused by *Haemophilus influenzae*, *Klebsiella spp.
*, *Staphylococcus aureus* (penicillinase-producing and non-penicillinase-producing strains), and *Streptococcus pneumoniae*; urinary tract infections (both complicated and uncomplicated) caused by *Pseudomonas aeruginosa*, *Escherichia coli*, *Proteus mirabilis*, and *Klebsiella spp.
*; intra-abdominal infections including peritonitis and intra-abdominal abscesses, often in conjunction with anaerobic agents; pelvic inflammatory disease; skin and skin structure infections; bone and joint infections; and septicemia/bacteremia.
It is also used in the treatment of uncomplicated gonorrhea caused by *Neisseria gonorrhoeae*.
Ceftizoxime is generally reserved for moderate to severe infections or when other first-line agents are not appropriate.

Dosage Information

Type	Guideline
Standard	Ceftizoxime is administered parenterally, either intravenously (IV) or intramuscularly (IM). The dosage and route of administration must be individualized based on the severity of the infection, the susceptibility of the causative organism, the patient's renal function, and overall clinical status. For adults, the typical dosage ranges from 1 to 4 grams administered every 8 to 12 hours. For severe or life-threatening infections, dosages up to 12 grams per day may be administered in divided doses (e.g., 2 grams every 8 hours or 3 grams every 6 hours). In cases of uncomplicated gonorrhea, a single 1-gram IM dose is often sufficient. Dosage adjustments are crucial for patients with impaired renal function (creatinine clearance <50 mL/min); reduced doses or extended dosing intervals are necessary to prevent accumulation and potential toxicity. Pediatric dosing is also weight-based and typically lower than adult doses. For IV administration, ceftizoxime should be reconstituted and diluted appropriately and administered over 3-5 minutes for direct IV push or over 30 minutes for intermittent infusion. Intramuscular injections should be given deep into a large muscle mass.

Type

Guideline

Standard

Ceftizoxime is administered parenterally, either intravenously (IV) or intramuscularly (IM). The dosage and route of administration must be individualized based on the severity of the infection, the susceptibility of the causative organism, the patient's renal function, and overall clinical status. For adults, the typical dosage ranges from 1 to 4 grams administered every 8 to 12 hours. For severe or life-threatening infections, dosages up to 12 grams per day may be administered in divided doses (e.g., 2 grams every 8 hours or 3 grams every 6 hours). In cases of uncomplicated gonorrhea, a single 1-gram IM dose is often sufficient. Dosage adjustments are crucial for patients with impaired renal function (creatinine clearance <50 mL/min); reduced doses or extended dosing intervals are necessary to prevent accumulation and potential toxicity. Pediatric dosing is also weight-based and typically lower than adult doses. For IV administration, ceftizoxime should be reconstituted and diluted appropriately and administered over 3-5 minutes for direct IV push or over 30 minutes for intermittent infusion. Intramuscular injections should be given deep into a large muscle mass.

Safety & Warnings

Common Side Effects

Like all antibiotics, ceftizoxime can cause a range of side effects, some of which can be serious.
Common adverse reactions include gastrointestinal disturbances such as diarrhea, nausea, and vomiting.
Local reactions at the injection site are frequently reported, including pain, tenderness, induration, and inflammation following intramuscular injection, and phlebitis or thrombophlebitis following intravenous administration.
Hypersensitivity reactions can manifest as rash, pruritus, urticaria, fever, or eosinophilia, with rare but severe cases progressing to anaphylaxis.
Hematologic abnormalities may include transient elevations in hepatic enzymes (AST, ALT, alkaline phosphatase), transient increases in blood urea nitrogen (BUN) and serum creatinine, and hematologic changes such as eosinophilia, leukopenia, neutropenia, thrombocytopenia, and, rarely, hemolytic anemia.
Other reported side effects include headache, dizziness, vaginitis, and oral candidiasis (thrush).
Prolonged use may lead to superinfection with resistant organisms or fungi.
The most serious gastrointestinal adverse effect is *Clostridium difficile*-associated diarrhea (CDAD), which can range from mild diarrhea to fatal colitis.

Serious Warnings

Black Box Warning: **Serious Warnings: Hypersensitivity Reactions and Clostridium difficile-Associated Diarrhea** While ceftizoxime does not carry an official FDA Black Box Warning, several serious safety concerns warrant prominent attention and careful management in clinical practice. Severe hypersensitivity reactions, including anaphylaxis, angioedema, and serious dermatologic reactions (e.g., Stevens-Johnson Syndrome, toxic epidermal necrolysis), have been reported with cephalosporin therapy. These reactions can be life-threatening or fatal. Patients with a history of severe penicillin allergy may be at an increased risk for hypersensitivity reactions to cephalosporins due to the potential for immunological cross-reactivity between beta-lactam classes. Therefore, a meticulous patient history regarding previous allergic reactions to any drug, especially beta-lactam antibiotics, is absolutely essential before initiating ceftizoxime treatment. Should any signs of an allergic reaction occur, ceftizoxime should be immediately and permanently discontinued, and appropriate medical intervention (e.g., epinephrine, corticosteroids, antihistamines, airway management, fluid resuscitation) must be promptly instituted. Furthermore, *Clostridium difficile*-associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, including ceftizoxime, and can range in severity from mild, self-limiting diarrhea to severe and potentially fatal pseudomembranous colitis. The disruption of normal colonic flora by antibiotics can lead to *C. difficile* overgrowth and toxin production. CDAD must be considered in all patients who present with diarrhea, abdominal pain, or fever following antibiotic use, sometimes occurring up to two months after cessation of therapy. If CDAD is suspected or confirmed, ongoing antibiotic therapy not directed against *C. difficile* may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment specifically for *C. difficile* (e.g., vancomycin, fidaxomicin), and surgical evaluation, as clinically indicated, should be initiated without delay. The potential for these serious adverse events necessitates vigilant monitoring and prompt intervention throughout the duration of ceftizoxime therapy and post-treatment follow-up.
Several critical warnings and precautions are associated with ceftizoxime use.
Patients should be carefully questioned about previous hypersensitivity reactions to cephalosporins, penicillins, or other drugs before initiating therapy due to the potential for severe, even fatal, hypersensitivity reactions.
Cross-reactivity between cephalosporins and penicillins can occur.
*Clostridium difficile*-associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, including ceftizoxime, and can range from mild to life-threatening colitis.
It is crucial to consider CDAD in patients presenting with diarrhea after antibiotic use.
Superinfections with non-susceptible organisms may occur with prolonged use, necessitating careful monitoring.
Dosage adjustments are mandatory in patients with renal impairment to prevent drug accumulation and potential neurotoxicity, including seizures.
Ceftizoxime may interfere with certain laboratory tests, such as causing a false-positive direct Coombs' test or falsely elevated urinary glucose values when using copper-reduction methods (e.
g.
, Benedict's or Fehling's solution).
Caution is advised in patients with a history of gastrointestinal disease, particularly colitis.

How it Works (Mechanism of Action)

Ceftizoxime is a bactericidal antibiotic that belongs to the third-generation cephalosporin class. Its primary mechanism of action involves the inhibition of bacterial cell wall synthesis. It achieves this by covalently binding to and inactivating penicillin-binding proteins (PBPs), which are enzymes located on the inner bacterial cell membrane. PBPs are crucial for the synthesis of peptidoglycan, a vital component of the bacterial cell wall responsible for maintaining structural integrity and shape. By binding to PBPs, ceftizoxime prevents the cross-linking of peptidoglycan strands, leading to the formation of defective and unstable cell walls. This structural compromise results in increased osmotic pressure within the bacterial cell, ultimately causing cell lysis and bacterial death. Ceftizoxime exhibits a broad spectrum of activity, including good activity against many Gram-negative bacteria (e.g., *Enterobacteriaceae*) and some Gram-positive bacteria, and it generally has good stability against many beta-lactamases produced by Gram-negative organisms, making it effective against some strains resistant to older cephalosporins.